Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ Amount of 0.1% hydrocortisone butyrate cream used during the study · adults with eczema
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 3.09 [2.14, 4.45]
1 study · 371 participants
Moderate
RR 0.95 [0.78, 1.16]
1 study · 377 participants
Low
RR 1.32 [1.17, 1.49]
1 study · 972 participants
Moderate
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
2 findings from 1 review
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher participant's self‐assessment of global response of improvement:… compared with corticosteroids (moderate certainty).
1 finding from 1 review
Adverse effects ‐ burning · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 2.91 [1.6, 5.28]
1 study · 371 participants
Moderate
RR 4.59 [3.1, 6.78]
1 study · 377 participants
Moderate
RR 3.79 [2.99, 4.81]
1 study · 972 participants
Moderate
Clearing or excellent improvement · people with discoid lupus erythematosus
1 finding from 1 review
At least 50% reduction in erythema · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life measure · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Change from baseline in disease severity according to participants ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants who rated treatment satisfaction as good to excellent · people with eczema
1 finding from 1 review
Number of participants reporting an adverse event · people with eczema
1 finding from 1 review
Change from baseline in disease severity as assessed by the investigators · people with eczema
1 finding from 1 review
Number of participants who experienced a flare · people with eczema
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in quality of life ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review